Quibim, a trailblazer in Precision Medicine, has unveiled QP-Brain, an AI-driven software revolutionizing early-stage neurodegenerative disease identification. Acquiring regulatory clearance in the US, EU, and UK, this innovation signifies a pivotal advancement. QP-Brain’s precision in quantifying MRI data, detecting subtle brain alterations, and visualizing findings vastly improves diagnosis accuracy. This breakthrough addresses the critical need for early detection, which is crucial in managing neurological diseases. Compliant with stringent data regulations, QP-Brain ensures secure data handling. Dr. Angel Alberich Bayarri, Quibim’s CEO, envisions this as a transformative leap toward enhancing patient outcomes.
Quibim’s launch of QP-Brain marks a watershed moment in neurodegenerative disease diagnosis. With neurological conditions affecting over a billion individuals globally and an aging population, early detection is paramount. Existing qualitative analysis often leads to late-stage disease identification. Quibim’s response, an AI-based tool, bridges this gap, offering precise quantitative analysis, secure data handling, and enhanced visualization. This innovation aims to empower clinicians, augmenting their capabilities for early diagnosis. The introduction of QP-Brain aligns with Quibim’s mission of merging AI technology with medical expertise to transform patient outcomes.
The launch of QP-Brain comes at a critical juncture when the prevalence of neurological diseases globally affects approximately one billion individuals, with a consistent rise among the aging population, where such conditions are more prevalent. There exists an escalating demand for precise assessments that can detect early changes in the brain.
Presently, the bulk of disease detection relies on qualitative analysis performed by radiologists and neurologists. However, this human-centric approach often limits the identification of neurodiseases to their advanced stages. To address this limitation, healthcare institutions require sophisticated, adaptable AI-powered tools capable of providing quantitative analysis and ensuring secure data transfer and storage for patients while streamlining clinicians’ workflow.
QP-Brain was meticulously developed by Quibim to facilitate the quantitative analysis of patients’ brains through an AI-driven tool that automatically quantifies and presents MRI Scan data results directly within Picture Archiving and Communication Systems (PACS). This technology enables the detection of subtle brain alterations by measuring brain regions, furnishing healthcare professionals with quantitative data that optimizes the radiological reporting process.
Moreover, Quibim’s innovative product offers quantification and visualization of imaging findings. This feature proves invaluable in identifying early-stage patterns of brain atrophy and neurodegenerative conditions such as Alzheimer’s, multiple sclerosis, vascular dementia, and frontotemporal dementia. It substantially enhances reporting accuracy while enabling early detection.
Prioritizing data security, QP-Brain complies with stringent regulations like the EU General Data Protection Regulation (GDPR) and the US Health Insurance Portability and Accountability Act (HIPAA). Its implementation ensures hospitals a secure means of processing and analyzing patient data. Furthermore, it can be effortlessly integrated into hospital servers behind firewalls via a secure cloud architecture.
Dr. Angel Alberich Bayarri, the founder and CEO of Quibim, expressed, “Obtaining regulatory clearance for QP-Brain® in the US, EU, and UK signifies a monumental achievement for Quibim and the early detection of neurological diseases. At Quibim, our mission is to develop AI technology that complements the pivotal role of medical experts, enhancing patient outcomes by enabling the early detection of neurological diseases and cancers far beyond current capabilities.”
Quibim’s QP-Brain stands as a beacon of hope in the realm of neurological disease diagnosis. Its regulatory clearance in key markets and AI-powered precision represent a seismic shift in early-stage detection. By enabling accurate quantification, visualization, and secure data handling, QP-Brain empowers clinicians to detect subtle brain alterations and neurodegenerative conditions at their incipient stages. This breakthrough signifies a transformative leap in medical technology, aligning with Quibim’s vision of amalgamating AI and human expertise for earlier disease detection, ultimately reshaping patient outcomes and enhancing the quality of life.
